Pricing for Oncology Biosimilars
To the Editor We wish to express several concerns regarding the article on hospital adoption and pricing for oncology biosimilars. First, we disagree with the statement that “Medicare bases its reimbursement for biosimilars on the high acquisition price for the biologic, not the low acquisition price for the biosimilar. A hospital that purchases a biosimilar at the biosimilar acquisition price thus gains from Medicare the difference between the biologic reimbursement and the biosimilar reimburse...
Original Source
Read the full article at Jamanetwork →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.